Workplace Sexual Harassment Ongoing in Women, Up for Men

Share this content:
Workplace Sexual Harassment Ongoing in Women, Up for Men
Workplace Sexual Harassment Ongoing in Women, Up for Men

TUESDAY, Nov. 21, 2017 (HealthDay News) -- Sexual harassment (SH) is a continuing occupational health problem, according to a report published recently in the Journal of Occupational Health Psychology.

James Campbell Quick, Ph.D., and M. Ann McFadyen, Ph.D., from the University of Texas at Arlington, discuss SH in the workplace and examine whether progress has been made toward reducing the burden of SH.

The researchers note that there was a 28 percent decrease in SH complaints over two decades. However, there has been an increase in complaints by males. Evidence exists that coworkers, subordinates, customers, and clients harass, as well as superiors, and women who violate traditional feminine ideals are also targets of harassment. Women tend to report more adverse effects after SH than men, including negative mood, eating disorders, drug and alcohol abuse, work turnover intentions, long-term anxiety, job stress, and/or burnout. Men who experience SH do not find the experience as anxiety provoking, although one study indicated that SH results in depression and anxiety for men. The lesbian, gay, bisexual, queer, and transgender workforce is more likely to face gender and sexual orientation SH than gender SH alone. Laws and company policies, together with training on these laws and policies, have been used to combat SH in the workplace.

"There has been progress on some fronts but not on others and the problem has morphed, becoming more complicated for a variety of reasons," the authors write.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »